Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.


  • Presentation
  • Question
  • Answer

Question
Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
signaling and angiogenesis

Question
Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
?

Question
Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
signaling and angiogenesis
If you want to change selection, open original toplevel document below and click on "Move attachment"

Parent (intermediate) annotation

Open it
Sorafenib, a compound that targets growth signaling and angiogenesis, should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.

Original toplevel document (pdf)

owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p2712

Summary

statusnot learnedmeasured difficulty37% [default]last interval [days]               
repetition number in this series0memorised on               scheduled repetition               
scheduled repetition interval               last repetition or drill

Details

No repetitions

Discussion

Do you want to join discussion? Click here to log in or create user.